Loading stock data…
NDRA
$4.95+0.08 (+1.64%)
Market ClosedLast close May 1
ENDRA Life Sciences Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ENDRA Life Sciences Inc. in the Healthcare sector is trading at $4.95. The stock is currently 59% below its 52-week high of $11.96, remaining 0.8% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why NDRA maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$4.95
Potential Upside
5%
Whystock Fair Value$5.20
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus1 analysts
Mean target$27.00+445.5%
Range$27.00 – $27.00
Fundamentals
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source comprising radio...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$6.70M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.22
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-574.93%
Volume
Today's trading volume
10,630
Recent News
NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision
ENDRA posts strong TAEUS Liver study data, showing high measurement reliability for MASLD monitoring and boosting its regulatory and commercial outlook.
Endra Life Sciences commences staking of HYPE digital asset holdings
ENDRA Life Sciences (NDRA) announced it has commenced staking its holdings of HYPE (HYPE-USD), the native token of the Hyperliquid ecosystem. The company said the move is designed to maximize the utility and return of its HYPE treasury. The initiative is guided by ARCA Investment Management and secured by Anchorage Digital. “Commencing our HYPE staking program is an essential evolution of our digital asset strategy,” said Alexander Tokman, CEO of ENDRA. “By partnering with industry leaders ARCA
Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition
MMSI is set to acquire C2 CryoBalloon from Pentax for $22M, strengthening its GI portfolio. Despite near-term dilution, the deal positions Merit for long-term growth in gastroenterology.